S&P 500   4,273.79
DOW   33,562.86
QQQ   354.90
Is Verizon’s 7% Yield Too Good To Pass Up?
NOTICE: Your retirement is in immediate danger (Ad)
Surging Over 100%: Small Cap Electric Boat Maker Makes Waves
The Most Upgraded Stocks In May Are Moving Higher 
NOTICE: Your retirement is in immediate danger (Ad)
Will Nvidia Be the Lifeline Intel Desperately Needs?
Here’s Why Disney’s MCU is Sinking in Quicksand
The single greatest medical breakthrough of all time? (Ad)
Buffett-Backed BYD Caught In The Chinese Government's Stimulus
Here’s What Driving the 125% YTD Gains for Upstart Holdings Stock
S&P 500   4,273.79
DOW   33,562.86
QQQ   354.90
Is Verizon’s 7% Yield Too Good To Pass Up?
NOTICE: Your retirement is in immediate danger (Ad)
Surging Over 100%: Small Cap Electric Boat Maker Makes Waves
The Most Upgraded Stocks In May Are Moving Higher 
NOTICE: Your retirement is in immediate danger (Ad)
Will Nvidia Be the Lifeline Intel Desperately Needs?
Here’s Why Disney’s MCU is Sinking in Quicksand
The single greatest medical breakthrough of all time? (Ad)
Buffett-Backed BYD Caught In The Chinese Government's Stimulus
Here’s What Driving the 125% YTD Gains for Upstart Holdings Stock
S&P 500   4,273.79
DOW   33,562.86
QQQ   354.90
Is Verizon’s 7% Yield Too Good To Pass Up?
NOTICE: Your retirement is in immediate danger (Ad)
Surging Over 100%: Small Cap Electric Boat Maker Makes Waves
The Most Upgraded Stocks In May Are Moving Higher 
NOTICE: Your retirement is in immediate danger (Ad)
Will Nvidia Be the Lifeline Intel Desperately Needs?
Here’s Why Disney’s MCU is Sinking in Quicksand
The single greatest medical breakthrough of all time? (Ad)
Buffett-Backed BYD Caught In The Chinese Government's Stimulus
Here’s What Driving the 125% YTD Gains for Upstart Holdings Stock
S&P 500   4,273.79
DOW   33,562.86
QQQ   354.90
Is Verizon’s 7% Yield Too Good To Pass Up?
NOTICE: Your retirement is in immediate danger (Ad)
Surging Over 100%: Small Cap Electric Boat Maker Makes Waves
The Most Upgraded Stocks In May Are Moving Higher 
NOTICE: Your retirement is in immediate danger (Ad)
Will Nvidia Be the Lifeline Intel Desperately Needs?
Here’s Why Disney’s MCU is Sinking in Quicksand
The single greatest medical breakthrough of all time? (Ad)
Buffett-Backed BYD Caught In The Chinese Government's Stimulus
Here’s What Driving the 125% YTD Gains for Upstart Holdings Stock
NASDAQ:EFTR

eFFECTOR Therapeutics (EFTR) Price Target & Analyst Ratings

$1.01
-0.16 (-13.68%)
(As of 06/5/2023 ET)
Compare
Today's Range
$1.00
$1.22
50-Day Range
$0.35
$1.17
52-Week Range
$0.34
$1.99
Volume
4.75 million shs
Average Volume
3.56 million shs
Market Capitalization
$42.82 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.50

eFFECTOR Therapeutics Consensus Rating and Price Target (2023)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Buy
Based on 3 Analyst Ratings

Consensus Analyst Price Target

$4.50
345.54% Upside
High Prediction$7.00
Average Prediction$4.50
Low Prediction$2.00
TypeCurrent
6/6/22 to 6/6/23
1 Month Ago
5/7/22 to 5/7/23
3 Months Ago
3/8/22 to 3/8/23
1 Year Ago
6/6/21 to 6/6/22
Consensus Rating
Buy
Buy
Buy
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
3 Buy rating(s)
2 Buy rating(s)
2 Buy rating(s)
4 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
1 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$4.50$4.50$5.00$19.64
Predicted Upside345.54% Upside761.82% Upside816.09% Upside91.09% Upside
Get eFFECTOR Therapeutics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for EFTR and its competitors with MarketBeat's FREE daily newsletter.


EFTR Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

EFTR Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

eFFECTOR Therapeutics Stock vs. The Competition

TypeeFFECTOR TherapeuticsMedical CompaniesS&P 500
Consensus Rating Score
3.00
2.66
2.48
Consensus RatingBuyBuyHold
Predicted Upside345.54% Upside1,270.87% Upside219.76% Upside
News Sentiment RatingNeutral News
Positive News
Positive News

Historical Target Prices and Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
5/26/2023Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeHold ➝ Buy
3/9/2023Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform$8.00 ➝ $7.00+1,288.04%
11/17/2022JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reni Benjamin
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetMarket Outperform$5.00 ➝ $2.00+270.37%
(Data available from 6/6/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)












EFTR Price Target - Frequently Asked Questions

What is eFFECTOR Therapeutics's consensus rating and price target?

According to the issued ratings of 3 analysts in the last year, the consensus rating for eFFECTOR Therapeutics stock is Buy based on the current 3 buy ratings for EFTR. The average twelve-month price prediction for eFFECTOR Therapeutics is $4.50 with a high price target of $7.00 and a low price target of $2.00. Learn more on EFTR's analyst rating history.

Do Wall Street analysts like eFFECTOR Therapeutics more than its competitors?

Analysts like eFFECTOR Therapeutics more than other Medical companies. The consensus rating score for eFFECTOR Therapeutics is 3.00 while the average consensus rating score for medical companies is 2.66. Learn more on how EFTR compares to other companies.

Is eFFECTOR Therapeutics being upgraded by Wall Street analysts?

Over the previous 90 days, eFFECTOR Therapeutics's stock had 1 upgrade by analysts.

Does eFFECTOR Therapeutics's stock price have much upside?

According to analysts, eFFECTOR Therapeutics's stock has a predicted upside of 761.82% based on their 12-month price targets.

What analysts cover eFFECTOR Therapeutics?

eFFECTOR Therapeutics has been rated by Credit Suisse Group, and Stifel Nicolaus in the past 90 days.


Stock Ratings Reports and Tools

This page (NASDAQ:EFTR) was last updated on 6/6/2023 by MarketBeat.com Staff

My Account -